

Cases from the Community: Investigators Discuss the Application of Available Research in the Care of Patients with Diffuse Large B-Cell Lymphoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **Loncastuximab tesirine binds to which of the following proteins?**
 - a. CD3/CD20
 - b. CD19
 - c. CD79b
 - d. XPO1
2. **Which of the following best describes the severity of cytokine release syndrome (CRS) observed with fixed-duration glofitamab with obinutuzumab pretreatment in the Phase II NP30179 study for patients with relapsed/refractory (R/R) large B-cell lymphoma?**
 - a. CRS was not observed
 - b. Most events were Grade 1
 - c. Most events were Grade 2-3
 - d. Most events were Grade 4
3. **Most responses observed with odronextamab in patients with R/R diffuse large B-cell lymphoma (DLBCL) in the Phase II ELM-2 trial were classified as...**
 - a. Stable disease
 - b. Partial responses
 - c. Complete responses
4. **Which of the following best describes progression-free survival (PFS) observations in patients who were ctDNA negative at end of therapy with pola-R-CHP versus R-CHOP for previously untreated DLBCL in an analysis of the Phase III POLARIX trial?**
 - a. PFS was equivalent with both regimens in ctDNA-negative patients
 - b. PFS in ctDNA-negative patients was longer with R-CHOP
 - c. PFS in ctDNA-negative patients was longer with Pola-R-CHP
5. **The EPCORE NHL-2 study is evaluating epcoritamab in combination with R-CHOP in which clinical setting?**
 - a. Patients with R/R double-hit DLBCL
 - b. Patients with DLBCL refractory to prior CAR T-cell therapy
 - c. Patients with newly diagnosed DLBCL
 - d. All of the above